Fortress Biotech Files 8-K on Oct 1, 2025
Ticker: FBIOP · Form: 8-K · Filed: Oct 1, 2025 · CIK: 1429260
Sentiment: neutral
Topics: 8-K, filing, pharmaceuticals
Related Tickers: FBIO
TL;DR
FBIO filed an 8-K on 10/1/25, check for updates.
AI Summary
Fortress Biotech, Inc. filed an 8-K on October 1, 2025, reporting other events and financial statements. The company, incorporated in Delaware, is in the pharmaceutical preparations industry and is located at 1111 Kane Concourse, Suite 301, Bay Harbor Islands, FL 33154. The filing also references Series Cumulative Redeemable Perpetual Preferred Stock.
Why It Matters
This 8-K filing provides an update on Fortress Biotech's corporate activities and financial reporting, which is crucial for investors to stay informed about the company's status.
Risk Assessment
Risk Level: low — This filing is a routine 8-K for other events and financial statements, not indicating any immediate significant risks.
Key Numbers
- 20251001 — Filing Date (The date the 8-K was filed.)
Key Players & Entities
- Fortress Biotech, Inc. (company) — Registrant
- October 1, 2025 (date) — Date of earliest event reported
- 1111 Kane Concourse, Suite 301, Bay Harbor Islands, FL 33154 (location) — Business Address
- 2834 (industry_code) — Standard Industrial Classification (Pharmaceutical Preparations)
- 001-35366 (company_id) — Commission File Number
FAQ
What specific 'Other Events' are detailed in this 8-K filing?
The provided text does not specify the 'Other Events' beyond listing it as an item information category.
What is the Standard Industrial Classification (SIC) code for Fortress Biotech, Inc. and what does it represent?
The SIC code is 2834, which corresponds to Pharmaceutical Preparations.
When was Fortress Biotech, Inc. formerly known as Coronado Biosciences Inc.?
The date of the name change from Coronado Biosciences Inc. to Fortress Biotech, Inc. was March 10, 2008.
What is the business address of Fortress Biotech, Inc.?
The business address is 1111 Kane Concourse, Suite 301, Bay Harbor Islands, FL 33154.
What type of preferred stock is mentioned in the filing?
The filing mentions Series Cumulative Redeemable Perpetual Preferred Stock.
Filing Stats: 432 words · 2 min read · ~1 pages · Grade level 10.3 · Accepted 2025-10-01 08:45:20
Filing Documents
- fbio-20251001x8k.htm (8-K) — 37KB
- fbio-20251001xex99.htm (EX-99) — 22KB
- fbio-20251001xex99001.jpg (GRAPHIC) — 8KB
- fbio-20251001xex99002.jpg (GRAPHIC) — 7KB
- 0001104659-25-095366.txt ( ) — 231KB
- fbio-20251001.xsd (EX-101.SCH) — 4KB
- fbio-20251001_def.xml (EX-101.DEF) — 15KB
- fbio-20251001_lab.xml (EX-101.LAB) — 17KB
- fbio-20251001_pre.xml (EX-101.PRE) — 15KB
- fbio-20251001x8k_htm.xml (XML) — 7KB
01. Other Events
Item 8.01. Other Events. On October 1, 2025, Fortress Biotech, Inc. issued a press release announcing that the U.S. Food and Drug Administration issued a complete response letter for CUTX-101 (copper histidinate). The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits . (d) Exhibits. The following exhibit is furnished herewith: 99 Exhibit Number Description 99.1 104 Press release of Fortress Biotech, Inc., dated October 1, 2025. Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Fortress Biotech, Inc. (Registrant) Date: October 1, 2025 By: /s/ David Jin David Jin Chief Financial Officer